|Articles|May 4, 2012

Paul Dobesh, PharmD, Points Out the Benefits of Combining Anticoagulant and Antiplatelet Treatments

Dr. Dobesh addresses the challenges of achieving efficacy without having the patient bleed when combining anticoagulant and antiplatelet treatments.

Paul Dobesh, PharmD, addresses the challenges in trying to simplify medication regiments in cardiovascular disease to improve clinical outcomes and increase adherence.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Paul Dobesh, PharmD, Points Out the Benefits of Combining Anticoagulant and Antiplatelet Treatments

Related Content

HMA-Venetoclax Beats Chemo in AML but Not for Everyone: Amir Fathi, MD

Resource Demands Challenge Community Oncology: Christos Vaklavas, MD

CAR T Access Challenged by Geography, Cost, and Treatment Delays

Access, Logistics Shape Multiple Myeloma Immunotherapy Decisions

Inside Myeloma’s Evolution From Death Sentence to Cure

Trending on AJMC

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

How Long-Acting Injectables Are Changing HIV Care

Less-Intensive Leukemia Regimen Outperforms Standard Chemo

FDA Approves Ropeginterferon Alfa-2b in Essential Thrombocythemia

Evolocumab Cuts Death Risk for a First Heart Attack or Stroke